Biohaven falls after depression drug fails mid-stage trial
24/12/2025 18:43
** Shares of drugmaker Biohaven BHVN.N fall 16% to $9 in extended trading ** Co says its drug, BHV-7000, did not meet the main goal of reduction of depressive symptoms in patients with major depressive disorder ** The drug was being studied in a proof-of-concept mid-stage study ** BHVN says it is not planning additional psychiatric clinical trials to keep resources focused on key priority areas of immunology, obesity and epilepsy in 2026 ** Up to last close, stock down 71% YTD (Reporting by Christy Santhosh) ((Christy.Santhosh@thomsonreuters.com))
Recent news on Biohaven
See all newsActing US FDA chief meets with rare disease groups to mend fences (updated)
Acting US FDA chief meets with rare disease groups to mend fences
Brief: Biohaven Reports New Clinical Data In Epilepsy With Opakalim, A Selective Kv7.2/7.3 Activator, Highlighting Seizure Control And Markedly Differentiated Tolerability Profile
Brief: Biohaven Files For Offering Of Up To $350 Million Common Shares - SEC Filing
Brief: Biohaven Ltd Files For Mixed Shelf Offering Size Not Disclosed - SEC Filing